Register to get unlimited Level 2

Company Announcements

Shire plc : Director/PDMR Shareholding

By GlobeNewswire

Director/PDMR Shareholding
 
August 9, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)
 
Notification of transaction by person discharging managerial responsibilities and person closely associated with them
 
1. Details of the person discharging managerial responsibilities ("PDMR") / person closely associated them ("PCA")
a) Name Kim Stratton / Peter Stratton
2. Reason for the notification
a) Position / status Head of International Commercial (PDMR) / PCA of Kim Stratton
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares")

 

 
Identification code ISIN: JE00B2QKY057
b) Nature of the transaction Transfer of Ordinary Shares held by Kim Stratton to a joint account held by Kim Stratton and Peter Stratton and the pledge of such Ordinary Shares as security for a loan.
c) Price(s) and volume(s) Price(s) Volume(s)
N/A 5,943
d) Aggregated information

- Aggregated volume

- Price 		N/A (single transaction)
e) Date of the transaction August 8, 2017
f) Place of the transaction Outside a trading venue

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations    
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 1256 894874
Media    
Lisa Adler lisa.adler@shire.com +1 617 588 8607
Debbi Ford debbi.ford@shire.com  +1 617 949 9083

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Shire plc via Globenewswire

Top of Page